[Comparative effects of terbutaline sulphate and ipratropium bromide on the respiratory system (author's transl)]. 1980

J I Villate Navarro, and V Sobradillo Peña, and V Atxotequi Iaraoligoitia, and A Salaverri Nalda, and C Orive Martínez

Bronchodilator action of two pharmacologically different drugs have been compared. Ipratropium bromide (Sch 1000) is a synthetic atropine derivative and terbutaline sulphate is a beta-stimulating agent. Twelve asthmatic patients and eight patients with chronic bronquitis received terbutaline 0.50 mg. and ipratropium 0.04 mg by aerosol inhalation. Both drugs were given at random on a consecutive-day schedule. All patients were clinically stable before treatment (basal FEV/VC less than 60 percent). Total lung capacity (TLC) forced expiratory volume (FEV), SRaw, and V'/V curves before and at 15, 60, 120, and 240 minutes after the produce administration were registered. Presence of side-effects was also checked. An intensive bronchodilator action was observed either after inhalation of ipratropium bromide or terbutaline, but statistical studies showed no significant differences between both drugs in relation to intensity and duration of their actions. Sch 1000 caused similar bronchodilator effects in all cases; a more intense effect in patients with chronic bronchitis could not be noticed. Evaluation of V'/V curve, and especially its relation to a same pulmonary volume, pointed out that both drugs act upon small respiratory airways. Advance side-effects were not present.

UI MeSH Term Description Entries
D009241 Ipratropium A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. N-Isopropylatropine,(endo,syn)-(+-)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane,Atrovent,Ipratropium Bromide,Ipratropium Bromide Anhydrous,Ipratropium Bromide Monohydrate,Ipratropium Bromide, (endo,anti)-Isomer,Ipratropium Bromide, (exo,syn)-Isomer,Ipratropium Bromide, endo-Isomer,Itrop,Sch-1000,Sch-1178,N Isopropylatropine,Sch 1000,Sch 1178,Sch1000,Sch1178
D012119 Respiration The act of breathing with the LUNGS, consisting of INHALATION, or the taking into the lungs of the ambient air, and of EXHALATION, or the expelling of the modified air which contains more CARBON DIOXIDE than the air taken in (Blakiston's Gould Medical Dictionary, 4th ed.). This does not include tissue respiration ( Breathing
D012129 Respiratory Function Tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. Lung Function Tests,Pulmonary Function Tests,Function Test, Pulmonary,Function Tests, Pulmonary,Pulmonary Function Test,Test, Pulmonary Function,Tests, Pulmonary Function,Function Test, Lung,Function Test, Respiratory,Function Tests, Lung,Function Tests, Respiratory,Lung Function Test,Respiratory Function Test,Test, Lung Function,Test, Respiratory Function,Tests, Lung Function,Tests, Respiratory Function
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000336 Aerosols Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents. Aerosol
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas

Related Publications

J I Villate Navarro, and V Sobradillo Peña, and V Atxotequi Iaraoligoitia, and A Salaverri Nalda, and C Orive Martínez
January 1979, The Indian journal of chest diseases & allied sciences,
J I Villate Navarro, and V Sobradillo Peña, and V Atxotequi Iaraoligoitia, and A Salaverri Nalda, and C Orive Martínez
September 1980, Praxis und Klinik der Pneumologie,
J I Villate Navarro, and V Sobradillo Peña, and V Atxotequi Iaraoligoitia, and A Salaverri Nalda, and C Orive Martínez
February 1994, Pulmonary pharmacology,
J I Villate Navarro, and V Sobradillo Peña, and V Atxotequi Iaraoligoitia, and A Salaverri Nalda, and C Orive Martínez
February 1993, Respiratory medicine,
J I Villate Navarro, and V Sobradillo Peña, and V Atxotequi Iaraoligoitia, and A Salaverri Nalda, and C Orive Martínez
January 1990, International journal of clinical pharmacology, therapy, and toxicology,
J I Villate Navarro, and V Sobradillo Peña, and V Atxotequi Iaraoligoitia, and A Salaverri Nalda, and C Orive Martínez
June 1990, Asian Pacific journal of allergy and immunology,
J I Villate Navarro, and V Sobradillo Peña, and V Atxotequi Iaraoligoitia, and A Salaverri Nalda, and C Orive Martínez
April 1976, Journal of clinical pharmacology,
J I Villate Navarro, and V Sobradillo Peña, and V Atxotequi Iaraoligoitia, and A Salaverri Nalda, and C Orive Martínez
January 1986, Respiration; international review of thoracic diseases,
J I Villate Navarro, and V Sobradillo Peña, and V Atxotequi Iaraoligoitia, and A Salaverri Nalda, and C Orive Martínez
December 1980, Nippon Ganka Gakkai zasshi,
J I Villate Navarro, and V Sobradillo Peña, and V Atxotequi Iaraoligoitia, and A Salaverri Nalda, and C Orive Martínez
August 1980, Nihon Kyobu Shikkan Gakkai zasshi,
Copied contents to your clipboard!